CARING,
A PROMISE AT CADYST
No. 1 in massive infusions for over 20 years
In line with its strategy to diversify the activities of Cadyst Group, founder and president Mr. Celestin TAWAMBA acquired a majority stake in Cinpharm in 2006 and later in SIPP in 2008, the pioneer in medicine manufacturing in Cameroon and the sub-region since 1989.
But in 2019, Cadyst Group parted ways with its subsidiary Cinpharm and focused the majority of its investments in the health sector on SIPP, aiming to maintain its leadership in the production of large volume infusion solutions. To date, the group has nearly tripled its market share.
Medium-term vision.
In the medium term, through a strategy of partnership and technology transfer with globally renowned pharmaceutical laboratories, expand and diversify our therapeutic ranges and become an essential link in the public health chain in our country, thereby becoming the most appreciated pharmaceutical manufacturer regardless of the criteria considered.
A MISSION EMBRACED
Sole manufacturer of infusion solutions since 1989,
Production capacity of 4 to 12 million infusion bags/year,
An investment of around 2.5 billion Francs Cfa in infrastructure and processes over the last 5 years.
OUR
THERAPEUTIC RANGE
Our therapeutic range consists mainly of solutions for infusion. They are used in various medical specialties, particularly in intensive care. These are sterile liquids composed of water and electrolytes (sodium, potassium, chloride, calcium) or nutrient compounds (glucose, lipids, amino acids) administered intravenously. They are part of the World Health Organization’s essential medicines list and the Ministry of Health’s guidelines.
